{"id":"tp-42891","type":"article-newspaper","title":"Geron Plans to Discontinue Late-Stage Rytelo Trial After Efficacy Concerns","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/42891","datePublished":"2026-10-28T19:54:09.000Z","dateModified":"2026-10-28T19:54:09.000Z","language":"en","abstract":"Geron shares fell more than 20% Wednesday as the company moved to end the study.","section":"Business","references":[]}